Importer of Controlled Substances; Notice of Application; Watson Pharma, Inc., 67675 [2012-27570]
Download as PDF
<![CDATA[
Federal Register / Vol. 77, No. 219 / Tuesday, November 13, 2012 / Notices
67675
952(a)(2)(B) may, in the circumstances
set forth in 21 U.S.C. 958(i), file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than December 13, 2012.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substance in schedules I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Schedule
Mix, Inc., 832 F.2d 601, 607 (D.C. Cir.
1987) (‘‘an agency may ordinarily
dispense with a hearing when no
genuine dispute exists’’); see also
Gregory F. Saric, M.D., 76 FR 16821
(2011) (stay denied in the face of
Respondent’s petition based on pending
state administrative action wherein he
was seeking reinstatement of state
privileges).
Accordingly, I hereby grant the
Government’s Motion for Summary
Disposition; and recommend that the
Respondent’s DEA registration be
revoked forthwith and any pending
applications for renewal be denied.
Dated: August 10, 2012.
/s/ JOHN J. MULROONEY, II,
Chief Administrative Law Judge.
[FR Doc. 2012–27554 Filed 11–9–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application; Watson Pharma,
Inc.
Pursuant to Title 21 Code of Federal
Regulations 1301.34(a), this is notice
that on August 28, 2012, Watson
Pharma, Inc., 2455 Wardlow Road,
Corona, California 92880–2882, made
application to the Drug Enforcement
Administration (DEA) for registration as
an importer of the following basic
classes of controlled substances:
Drug
Schedule
srobinson on DSK4SPTVN1PROD with
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
II
II
II
II
Jkt 229001
BILLING CODE 4410–09–P
Drug Enforcement Administration
challenge to the state medical board action actively
pending in the state courts. Michael G. Dolin, M.D.,
65 FR 5661, 5662 (2000).
17:08 Nov 09, 2012
[FR Doc. 2012–27570 Filed 11–9–12; 8:45 am]
DEPARTMENT OF JUSTICE
The company plans to import the
listed controlled substances for
analytical testing and clinical trials.
The import of the above listed basic
classes of controlled substances will be
granted only for analytical testing and
clinical trials. This authorization does
not extend to the import of a finished
FDA approved or non-approved dosage
form for commercial distribution in the
United States.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances listed in schedules I or II,
which fall under the authority of section
1002(a)(2)(B) of the Act 21 U.S.C.
VerDate Mar<15>2010
Dated: November 5, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Importer of Controlled Substances,
Notice of Registration, SA INTL GMBH
C/O., Sigma Aldrich Co., LLC.
By Notice dated August 17, 2012, and
published in the Federal Register on
August 20, 2012, 77 FR 50162, SA INTL
GMBH C/O., Sigma Aldrich Co., LLC.,
3500 Dekalb Street, St. Louis, Missouri
63118, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
the following basic classes of controlled
substances:
Drug
Schedule
Cathinone (1235) ..........................
Methcathinone (1237) ..................
N-Ethylamphetamine (1475) ........
Aminorex (1585) ...........................
Gamma
Hydroxybutyric
Acid
(2010).
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
I
I
I
I
I
Drug
Methaqualone (2565) ...................
Alpha-ethyltryptamine (7249) .......
Ibogaine (7260) ............................
Lysergic acid diethylamide (7315)
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Mescaline (7381) ..........................
4-Bromo-2,5dimethoxyamphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine
(7392).
4-Methyl-2,5dimethoxyamphetamine (7395).
2,5-Dimethoxyamphetamine
(7396).
3,4-Methylenedioxyamphetamine
(7400).
N-Hydroxy-3,4methylenedioxyamphetamine
(7402).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3,4Methylenedioxymethamphetamine (7405).
4-Methoxyamphetamine (7411) ...
Bufotenine (7433) .........................
Diethyltryptamine (7434) ..............
Dimethyltryptamine (7435) ...........
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
1-[1-(2Thienyl)cyclohexyl]piperidine
(7470).
N-Benzylpiperazine (7493) ...........
Heroin (9200) ...............................
Normorphine (9313) .....................
Etonitazene (9624) .......................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Methylphenidate (1724) ................
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
Glutethimide (2550) ......................
Nabilone (7379) ............................
Phencyclidine (7471) ....................
Cocaine (9041) .............................
Codeine (9050) .............................
Diprenorphine (9058) ...................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Diphenoxylate (9170) ...................
Ecgonine (9180) ...........................
Ethylmorphine (9190) ...................
Hydrocodone (9193) .....................
Levorphanol (9220) ......................
Meperidine (9230) ........................
Methadone (9250) ........................
Morphine (9300) ...........................
Thebaine (9333) ...........................
Opium, powdered (9639) .............
Levo-alphacetylmethadol (9648) ..
Oxymorphone (9652) ...................
Fentanyl (9801) ............................
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to import the
listed controlled substances for sale to
research facilities for drug testing and
analysis.
No comments or objections have been
received. DEA has considered the
E:\FR\FM\13NON1.SGM
13NON1
]]>Agencies
[Federal Register Volume 77, Number 219 (Tuesday, November 13, 2012)]
[Notices]
[Page 67675]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-27570]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application; Watson
Pharma, Inc.
Pursuant to Title 21 Code of Federal Regulations 1301.34(a), this
is notice that on August 28, 2012, Watson Pharma, Inc., 2455 Wardlow
Road, Corona, California 92880-2882, made application to the Drug
Enforcement Administration (DEA) for registration as an importer of the
following basic classes of controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Amphetamine (1100)......................... II
Methylphenidate (1724)..................... II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
------------------------------------------------------------------------
The company plans to import the listed controlled substances for
analytical testing and clinical trials.
The import of the above listed basic classes of controlled
substances will be granted only for analytical testing and clinical
trials. This authorization does not extend to the import of a finished
FDA approved or non-approved dosage form for commercial distribution in
the United States.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic classes of controlled
substances listed in schedules I or II, which fall under the authority
of section 1002(a)(2)(B) of the Act 21 U.S.C. 952(a)(2)(B) may, in the
circumstances set forth in 21 U.S.C. 958(i), file comments or
objections to the issuance of the proposed registration and may, at the
same time, file a written request for a hearing on such application
pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR
1316.47.
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than December 13, 2012.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR 1301.34(b), (c),
(d), (e), and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, 40 FR 43745-46, all applicants
for registration to import a basic class of any controlled substance in
schedules I or II are, and will continue to be, required to demonstrate
to the Deputy Assistant Administrator, Office of Diversion Control,
Drug Enforcement Administration, that the requirements for such
registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR
1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: November 5, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2012-27570 Filed 11-9-12; 8:45 am]
BILLING CODE 4410-09-P
